Predisposing factors for the development of diabetic ketoacidosis with lower than anticipated glucose levels in type 2 diabetes patients on SGLT2-inhibitors: a review Adeboye Olakunle BamgboyeIsaac Oluwadamilare OniAndrew Collier Review 26 November 2020 Pages: 651 - 657
Serum 4β-hydroxycholesterol increases during fluconazole treatment Dieter LütjohannFrans StellaardBruno G Oertel Clinical Trial Open access 17 November 2020 Pages: 659 - 669
Influence of formulation and route of administration on ketamine’s safety and tolerability: systematic review Paul GlueBruce RussellNatalie J. Medlicott Clinical Trial 18 November 2020 Pages: 671 - 676
The scientific basis of rational prescribing. A guide to precision clinical pharmacology based on the WHO 6-step method G. A. RongenP. MarquetOn behalf of the EACPT research working group Special Article Open access 18 November 2020 Pages: 677 - 683
The impacts of race and regimens on the efficacy and safety of paclitaxel and platinum combination treatment for patients with advanced non-small cell lung cancer Chenyang ZhaoFengli WangLujin Li Pharmacodynamics 29 March 2021 Pages: 685 - 695
CYP450 polymorphisms and clinical pharmacogenetics of ibuprofen after lower third molar extraction Giovana M. WeckwerthThiago J. DionísioCarlos F. Santos Pharmacogenetics 17 November 2020 Pages: 697 - 707
Implementation and management outcomes of pharmacogenetic CYP2C19 testing for clopidogrel therapy in clinical practice Stefan RussmannAli RahmanyMarkus Béchir Pharmacogenetics Open access 26 November 2020 Pages: 709 - 716
An open-label, positron emission tomography study of the striatal D2/D3 receptor occupancy and pharmacokinetics of single-dose oral brexpiprazole in healthy participants Dean F. WongArash RaoufiniaHiroto Kuwabara Pharmacokinetics and Disposition Open access 16 November 2020 Pages: 717 - 725
Normal fat mass cannot be reliably estimated in typical pharmacokinetic studies Roeland E. WasmannElin M. SvenssonRob ter Heine Pharmacokinetics and Disposition Open access 18 November 2020 Pages: 727 - 733
Population pharmacokinetics of cefazolin before, during and after cardiopulmonary bypass in adult patients undergoing cardiac surgery Mizuho AsadaMasashi NagataMasato Yasuhara Pharmacokinetics and Disposition 19 November 2020 Pages: 735 - 745
Association between lipid-lowering agents and severe hyponatremia: a population-based case–control study Jakob SkovHenrik FalhammarBuster Mannheimer Pharmacoepidemiology and Prescription Open access 19 November 2020 Pages: 747 - 755
Potentially inappropriate medication in acute hospitalized elderly patients with polypharmacy: an observational study comparing PRISCUS, STOPP, and Beers criteria Lorena de Agustín SierraJaime Rodríguez SalazarBenito García Díaz Pharmacoepidemiology and Prescription 18 November 2020 Pages: 757 - 766
Arrhythmias related to antipsychotics and antidepressants: an analysis of the summaries of product characteristics of original products approved in Germany Mohamed ElsayedEmaad Abdel-kahaarCarlos Schönfeldt-Lecuona Pharmacoepidemiology and Prescription Open access 23 November 2020 Pages: 767 - 775
Potentially inappropriate prescribing in older hospitalized Dutch patients according to the STOPP/START criteria v2: a longitudinal study Birgit A. Damoiseaux-VolmanStephanie MedlockAmeen Abu-Hanna Pharmacoepidemiology and Prescription Open access 02 December 2020 Pages: 777 - 785
Antimicrobial stewardship: can we add pharmacovigilance networks to the toolbox? Jean Marie Vianney HabarugiraAlbert Figueras Point of View 16 November 2020 Pages: 787 - 790
Prediction of lopinavir/ritonavir effectiveness in COVID-19 patients: a recall of basic pharmacology concepts Dario CattaneoMario CorbellinoCristina Gervasoni Letter to the Editor 25 November 2020 Pages: 791 - 792
Reply to the letter to the Editor “Prediction of lopinavir/ritonavir effectiveness in COVID-19 patients: a recall of basic pharmacology concepts” Nicolas SimonJean Claude Alvarez Letter to the Editor 26 November 2020 Pages: 793 - 794
